Product Description
Relebactam is a beta-lactamase inhibitor with the ability to inhibit a broad spectrum of beta-lactamases such as class A and class C beta-lactamases, including carbapenemases. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32060929/)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Croatia | Cyprus | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Taiwan | United Arab Emirates | United Kingdom | United States
Approved Indications: Urinary Tract Infections | Nephritis | Pyelonephritis
Known Adverse Events: Hypertension | Phlebitis | Headache | Diarrhea
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Pneumonia, Bacterial|Pneumonia, Ventilator-Associated
Phase 2: Acute Respiratory Distress Syndrome|Febrile Neutropenia
Phase 1: Sepsis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2021-01957 | P2 |
Completed |
Febrile Neutropenia|Acute Respiratory Distress Syndrome |
2023-10-06 |
|
| Open-label Active-control Pediatric Safety, Efficacy, PK Study of MK-7655A | P3 |
Active, not recruiting |
Unknown |
2023-06-26 |
|
| NCT04493151 | P1 |
Completed |
Sepsis |
2023-05-31 |
|
| IMI/REL (MK-7655A) vs. PIP/TAZ for Treatment of Subjects with HABP/VABP | P3 |
Completed |
Pneumonia, Bacterial|Pneumonia, Ventilator-Associated |
2022-01-09 |